
Some Africans have seen a big belly as a sign of wealth. It's killing them
In many African cultures, a large belly has traditionally signified wealth and prosperity. However, this long-held perception is now proving deadly as obesity-related illnesses become a leading cause of death.
In Kenya, the association between weight and status is particularly evident. Overweight politicians often earn the moniker "Boss" or "Mkubwa" – Swahili for "big man" – a term reflecting the cultural view of girth as a symbol of success. This perception, however, masks a growing health crisis. Obesity contributes significantly to non-communicable diseases like diabetes, now the leading cause of death in Kenya. According to the Kenyan health ministry, these diseases account for 39% of fatalities annually.
This alarming trend has prompted a shift in attitudes, particularly among younger politicians. Leaders such as the governors of Nairobi and Mombasa have begun publicly discussing their weight loss journeys, challenging traditional views and highlighting the importance of a healthy lifestyle. This marks a potential turning point in a culture where weight has long been equated with wealth, suggesting a growing awareness of the serious health risks associated with obesity.
In a country where the government has said almost a third of the population is still unable to fulfill food needs, 13% adults are obese, according to the 2025 World Obesity Atlas. The contrast highlights the country's growing inequality and the popularity of fast and processed foods by those with rising incomes.
Perceptions about obesity can affect financial and other decisions. In neighboring Uganda, microfinance institutions vetted loan applicants based on their weight, and those overweight were considered more able to repay loans, according to a study published by the American Economic Review in 2023.
'Most people feel like when I start making money, I have to look like the money itself by being fat or obese,' said Kenyan nutritionist Felix Okoth. 'They however don't realize that they are predisposing themselves to these lifestyle conditions such as diabetes and hypertension.'
The World Health Organization 's Africa director has called the rising trend a 'ticking time bomb" for the continent with the world's youngest and fastest growing population.
Some are trying to change the conversation around weight. A former senator in Kenya, Cleophas Malala, has described how a 15-hour flight to the U.S. left him in pain and how doctors advised him to reduce.
From a starting weight of 138 kilograms (304 pounds), he embarked on a non-solid diet for 90 days. Though he didn't disclose his current weight, before-and-after photos show him noticeably slimmer.
'My colleagues in parliament were mad that I left the 'club' after I lost weight,' the 39-year-old has said.
Stephen Ogweno, who had childhood obesity and later became a public health advocate, said most Kenyan legislators don't see the issue as a problem.
'These discussions are held in parliament where most MPs have big bellies, and so admitting that it concerns them, too, would be a good place to start,' he said.
Kenyan President William Ruto has spoken publicly about the need to be fit for work. He had to reassure Kenyans in 2023 that he was okay after online speculation about his health following weight loss.
'I decided to cut it down because the task ahead was not easy,' he told journalists.
Increasing incomes, proliferation of fast-food outlets in urban areas, sedentary lifestyles and lack of infrastructure that promotes physical activity have been named as probable causes of rising obesity in developing countries.
'We need to make sure that when we move away from lack of food, we are not going to the wrong food groups,' said a Kampala-based doctor, Miriam Laker Oketta.
Public health campaigns will help demystify the perception that weight is an indication of wealth, said Caroline Kirui, the Africa director for Project ECHO, an information-sharing platform for healthcare workers.
Gyms, weight loss drugs and surgeries are being increasingly advertised in Kenya.
But approaches such as the Ozempic weight-loss drug have left some users like Caroline Havi dissatisfied. She said she turned to a one-meal-a-day diet instead and hopes to eventually reduce her weight from 105 kilograms to 70 'without spending so much."
In South Africa, obesity-related deaths due to non-communicable diseases have surpassed HIV-related deaths, according to the WHO. The 2025 World Obesity Atlas said 32% of South Africa 's adults are obese.
The perception that weight is a symbol of wealth is slowly changing, said Rebone Ntsie, nutrition director at the National Department of Health.
'There are those who still see it like that, but people are also seeing the dangers and its no longer celebrated as a sign of dignity, beauty, respect, social status," she said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Sun
4 hours ago
- The Sun
I recovered from booze & drug addiction then piled on 3 stone – Mounjaro was the only thing that helped
CAT Sims has opened up about turning to Mounjaro after quitting booze and drugs lead her turning to food and piling on three stones. Author and podcaster Cat, 43, from London, hailed the weight loss jab as 'rehab for food' and praised it for being a 'silver bullet.' 8 8 Cat has previously opened up about battling an alcoholic and drug addiction - but managed to kick the habit of having a bottle of wine a night and taking cocaine regularly. However, she then struggled with food. Speaking on the podcast, Made by Mammas, she candidly shared that she is 'all or nothing' and food is a 'big issue for her.' Cat, who is married to husband Jimmy and has two daughters, Billie and Bo, explained: 'I think actually that was probably my first addiction. 'But for me, I'm sure there are people who can balance who can moderate. I do not have that gene. 'I've recently started Mounjaro, I've recently started the weight loss jabs. 'I was three stone heavier than I was when I gave up booze. 'I think people think if you give up booze you're going to lose a little weight. 'I lost nothing. I just went straight into food and chocolate and sugar.' She then explained how Mounjaro has helped her 'food addiction', and said: 'For me it's like rehab for food addiction. 'You're locked down and while you're there you do all the work, so that when you come out of rehab you can do it on your own. 'And that's what Mounjaro is for me.' Cat shared how she feels like her food addiction is now gone thanks to the controversial weight loss jab. 8 8 8 She added: 'I have no cravings for the crappy food or the ultra processed stuff. 'It was always a difficult thing because with booze and alcohol I was always like I can just abstain, I don't have to have those things, but food, I can't just not eat. 'But now I think doing the work I'm doing while I'm on the injections has made me realise that I can abstain from the ultra processed stuff. 'There are side effects, as there are with any drug or medication or anything that you put into you that isn't naturally supposed to be, but for me, it's been a silver bullet in terms of helping me manage what is essentially a food addiction, you know, and also I'm perimenopausal.' 8 8 8 MOUNJARO TAKEOVER Mounjaro injections are licensed for patients with type 2 diabetes and are administered every seven days. They are also available to assist those who are clinically obese (with a Body Mass Index of 30 or over). The drugs, which have been widely regarded as 'fat jabs', can be prescribed by a practitioner - such as a doctor, nurse or a pharmacist-independent prescriber. But increasingly, we are seeing more and more people buying them through online pharmacies, without sufficient checks. Not only this, but recently, figures from the Medicines and Healthcare products Regulatory Agency revealed that fat jabs had been linked to 82 deaths across the UK. Everything you need to know about fat jabs Weight loss jabs are all the rage as studies and patient stories reveal they help people shed flab at almost unbelievable rates, as well as appearing to reduce the risk of serious diseases. Wegovy – a modified version of type 2 diabetes drug Ozempic – and Mounjaro are the leading weight loss injections used in the UK. Wegovy, real name semaglutide, has been used on the NHS for years while Mounjaro (tirzepatide) is a newer and more powerful addition to the market. Mounjaro accounts for most private prescriptions for weight loss and is set to join Wegovy as an NHS staple this year. How do they work? The jabs work by suppressing your appetite, making you eat less so your body burns fat for energy instead and you lose weight. They do this my mimicking a hormone called GLP-1, which signals to the brain when the stomach is full, so the drugs are officially called GLP-1 receptor agonists. They slow down digestion and increase insulin production, lowering blood sugar, which is why they were first developed to treat type 2 diabetes in which patients' sugar levels are too high. Can I get them? NHS prescriptions of weight loss drugs, mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics. Typically a patient will have to have a body mass index (BMI) of 30 or higher, classifying them as medically obese, and also have a weight-related health condition such as high blood pressure. GPs generally do not prescribe the drugs for weight loss. Private prescribers offer the jabs, most commonly Mounjaro, to anyone who is obese (BMI of 30+) or overweight (BMI 25-30) with a weight-related health risk. Private pharmacies have been rapped for handing them out too easily and video calls or face-to-face appointments are now mandatory to check a patient is being truthful about their size and health. Are there any risks? Yes – side effects are common but most are relatively mild. Around half of people taking the drug experience gut issues, including sickness, bloating, acid reflux, constipation and diarrhoea. Dr Sarah Jarvis, GP and clinical consultant at said: 'One of the more uncommon side effects is severe acute pancreatitis, which is extremely painful and happens to one in 500 people.' Other uncommon side effects include altered taste, kidney problems, allergic reactions, gallbladder problems and hypoglycemia. Evidence has so far been inconclusive about whether the injections are damaging to patients' mental health. Figures obtained by The Sun show that, up to January 2025, 85 patient deaths in the UK were suspected to be linked to the medicines.


Daily Mail
11 hours ago
- Daily Mail
EXCLUSIVE Ozempic shockingly linked to 'silent cancer' that's rising in young people as doctors issue warning
Ozempic and similar weight loss drugs may raise the risk of kidney cancer, a major study suggests. But the fat-melting shots lower the risk of over a dozen other cancers — meaning the benefits may still outweigh the risks. Your browser does not support iframes. Your browser does not support iframes. Your browser does not support iframes.


The Independent
12 hours ago
- The Independent
Wegovy use spikes among teens as doctors grapple with obesity crisis
New data indicates that American teenagers are increasingly using the weight-loss drug Wegovy, as confidence in its use for young people with obesity grows among families and doctors. According to an analysis by health data firm Truveta, the average rate of teenagers starting treatment with the highly effective Novo Nordisk drug increased by 50 per cent in 2024, reaching 14.8 prescriptions per 100,000 adolescents. This is a notable rise from 9.9 prescriptions per 100,000 in 2023, which was the first full year Wegovy was available to those aged 12 and older. The rate has continued to climb, with the first three months of this year showing an average of 17.3 new prescriptions per 100,000 teens. However, this figure still represents a small fraction of the estimated 23,000 out of every 100,000 teens in the country who are living with obesity, and the adoption rate is significantly slower than that of U.S. adults. "It's promising that more young people are using these medications, but it's still a very small percentage of patients with severe obesity that are getting access to them," said Dr Cate Varney, director of obesity medicine at the University of Virginia Health system. "When lifestyle changes alone are insufficient, we need these additional tools." For its analysis, Truveta reviewed the electronic health records of 1.3 million patients ages 12 through 17. The data covers 30 U.S. health systems with more than 900 hospitals and 20,000 clinics across the country. The analysis did not include other GLP-1 drugs, including Novo's Ozempic and Eli Lilly 's Zepbound, which are not approved to treat obesity in adolescents, or compounded versions of these therapies. Wegovy became an option to treat adolescents in late 2022 after decades in which the conventional approaches of diet, exercise and counseling largely failed. About 8 million American teens, or 23 per cent of people ages 12 to 19, have obesity, up from 5 per cent in 1980, according to U.S. government data. Young people with obesity run a much higher risk of developing chronic, costly, life-shortening conditions like type 2 diabetes and cardiovascular and liver diseases. In January 2023, the American Academy of Pediatrics strongly recommended that doctors provide weight-loss drugs to children with obesity starting at age 12. Yet the medical community has not uniformly embraced GLP-1s for adolescents. Some doctors are hesitant because the drugs' long-term safety for children during a critical phase of development is unknown, and the treatments may need to be used indefinitely. Overall, there are limited options for many teens and their parents because insurance plans often do not cover any treatment for obesity, including intensive behavioral counseling, visits with a dietician or the new GLP-1 medications. An option for some At Nemours Children's Hospital in Wilmington, Delaware, the Healthy Weight and Wellness Clinic treated about 2,000 adolescent patients in 2024. About 25 per cent were prescribed Wegovy or another GLP-1 medication, said Dr Thao-Ly Phan, the clinic's medical director. The number of adolescents with a GLP-1 prescription nearly doubled from 2023. On average, their patients taking a GLP-1 drug lost 15 pounds (6.8 kg) within 6 to 12 months, and nearly 30 pounds after more than a year. For many of the other patients, the medications were not an option, either because of insurance hurdles or concern within families about potential risks. Other teens opted for lifestyle changes or older, cheaper weight-loss drugs, with some success. "It is important for us to continue to monitor and better understand outcomes from the medications – both positive and negative – before widespread use," Phan said. U.S. Health Secretary Robert F. Kennedy Jr. has criticized the idea of prescribing Ozempic or Wegovy widely to children to treat obesity. In a federal health report he released in May, GLP-1 drugs were cited as an example of the "overmedicalization of our kids." It noted a lack of "long-term safety data, raising the specter of unforeseen problems that interrupt, damage, or impair metabolism and growth development." Novo in a statement said semaglutide, the active ingredient in Wegovy and Ozempic, 'did not appear to affect growth or pubertal development' during its clinical trials involving teens. For many adults, Novo said, obesity starts in childhood or adolescence, and "we are confident in the proven safety and efficacy of our GLP-1 medicines." Eli Lilly's weight-loss drug Zepbound is in late-stage clinical trials for use by adolescents. It said that "there has been no evidence to date suggesting impairment in growth or metabolism" from GLP-1 medications. Dr Robert Siegel, a pediatrician and director of the Center for Better Health and Nutrition at Cincinnati Children's Hospital, said about 15 per cent of adolescents being treated there were prescribed Wegovy or a similar GLP-1 medication from July 2021 to July 2023. They include patients being treated for type 2 diabetes for which the GLP-1 drugs were originally developed. Siegel said he prefers to start teens on three to six months of intensive lifestyle management before even considering medication. While obesity specialists can help navigate potential risks from the drugs, many primary-care providers need more training, he said. They may not have the equipment to monitor for the loss of muscle mass – a side effect of these medicines – or lack the resources to work with families over an extended period on healthier eating and exercise. "These medications are likely to be needed for a very long time to maintain weight," Siegel said, "and we only have a relatively short-term experience with them."